Mar 27, 2025 8:00am EDT BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints
Mar 17, 2025 4:16pm EDT Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results
